Armored CAR-T Cells: Fortifying the Future of Cancer Therapy

Le résumé fourni par la source

Chimeric Antigen Receptor (CAR)-T cell therapy has emerged as a groundbreaking approach in cancer immunotherapy, offering personalized and targeted treatment for hematologic malignancies. However, conventional CAR-T cells face significant challenges, including limited persistence, immune evasion, and an immunosuppressive tumor microenvironment. Armored CAR-T cells, an advanced generation of engineered T cells, address these limitations by incorporating additional genetic modifications to enhance their efficacy, persistence, and resistance to tumor-induced immunosuppression. This review examines the evolution, mechanisms, and clinical applications of armored CAR-T cells, highlighting their role in overcoming the limitations of traditional CAR-T therapy. By integrating cytokine signaling, co-stimulatory molecules, and checkpoint inhibitors, armored CAR-T cells demonstrate superior anti-tumor responses in preclinical and clinical studies. Despite promising results, challenges, such as toxicity, antigen escape, and regulatory complexities, remain. Future advancements in gene editing, combinational therapies, and bioengineering strategies hold the potential to optimize armored CAR-T cell therapy, broadening its applicability to solid tumors and improving long-term patient outcomes. This review highlights the current state of armored CAR-T therapy, its clinical implications, and future directions in revolutionizing cancer treatment.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.